Esperion Therapeutics ESPR Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's weighted average exercise price of outstanding options?
- Esperion Therapeutics (ESPR) reported weighted average exercise price of outstanding options of $5.06 in Q1 2026.
- How has Esperion Therapeutics's weighted average exercise price of outstanding options changed year-over-year?
- Esperion Therapeutics's weighted average exercise price of outstanding options decreased by 22.9% year-over-year, from $6.56 to $5.06.
- What is the long-term trend for Esperion Therapeutics's weighted average exercise price of outstanding options?
- Over 5 years (2020 to 2025), Esperion Therapeutics's weighted average exercise price of outstanding options has grown at a -32.1% compound annual growth rate (CAGR), from $40.24 to $5.81.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.